Level A· Stronger Clinical EvidenceSystematic ReviewPubMed

Mesenchymal stromal cell therapy for scarring: a systematic review of clinical and preclinical studies.

Hansen L., Laustsen-Kiel CM., Rangatchew F., Jensen CH., Andersen DC., Holmgaard R.

Systematic Review on Scar, Immune Modulation, published in Stem Cells (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Stem Cells (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41143553
DOI
10.1093/stmcls/sxaf070

Abstract (original English)

Mesenchymal stromal/stem cell (MSC) transplantation has emerged as a promising therapeutic strategy for managing cutaneous scarring, an issue associated with significant aesthetic and functional morbidity. This systematic review evaluates the potential of MSCs to modulate scarring, highlighting their efficacy and distinct mechanisms from traditional scar treatments. The review adheres to the PRISMA guidelines. We followed a prospectively registered protocol and conducted comprehensive searches in the PubMed and EMBASE databases. Eleven studies, including preclinical and clinical trials, met the inclusion criteria. Study quality was assessed using the ROBINS-I and Cochrane Risk of Bias 2 tools. MSC and MSC-conditioned medium therapies derived from adipose tissue, bone marrow, or the umbilical cord demonstrated significant improvements in scar appearance, reductions in thickness and volume, and beneficial remodeling of collagen structures. MSC treatment positively influenced inflammatory and immunomodulatory responses, as reflected by the regulation of cytokines and fibrotic biomarkers. However, the heterogeneity in methodologies, MSC sources, and administration routes limits the ability to make conclusive statements. Furthermore, insufficient transparency in MSC preparation challenges clinical reproducibility and application. MSC therapy is becoming increasingly important in reg

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsCicatrixAnimals

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research